Goldman, MD Medical Reviewer Anna L
The National Eating Disorders Association offers an online questionnaire to help people assess whether they are experiencing an eating disorder
Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
This process removes most of the lactose, fats, and carbohydrates, resulting in a protein powder that is over 90% pure protein by weight
Instead, in the present study, we focused on food preoccupation, reflecting a conceptual shift that dysregulated eating behaviors are a result of disruption in both hedonic and homeostatic processes (for more information, see Methods) 1,4,11
